

**Ref No. NLL/CS/2023-263**

**May 26, 2023**

To  
National Stock Exchange of India Limited  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai 400 051  
**Symbol: NECLIFE**

BSE Limited  
Corporate Relationship Department,  
P J Towers, Dalal Street,  
Mumbai 400 001  
**Scrip Code: 532649**

**Sub: Disclosure of Related Party Transactions.**

**Ref.: SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021**

Dear Sir/Madam,

Pursuant to Compliance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and captioned circular, please find enclosed the disclosure on Related Party Transactions for half year period from October 01, 2022, to March 31, 2023.

This is for your information and records.

Yours faithfully,

**For Nectar Lifesciences Limited**

(Neha Vaishnav)  
**Company Secretary & Compliance Officer**

Encl. As above



17	Nectar Lifesciences Limited		Sanjiv (HUF)	Promoter/Director have significant Influence	Unsecured Interest free loan received	Not Applicable	Not Applicable	-	1,000.00	1,000.00	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
18	Nectar Lifesciences Limited		Mr. Sanjiv Goyal	Chairman & Managing Director	Unsecured Interest free loan received	Note 3	Not Applicable	300.00	-	300.00	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
19	Nectar Lifesciences Limited		Mrs. Raman Goyal	Relative of Chairman & Managing Director	Rent	42.00	No	42.00	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

Note 1. Audit Committee approval has been received on all perpetual transactions for the term of Managerial Remuneration/ Salary to KMPs/ Sitting Fee/ CSR Expenditure. Further approvals from Board / members have been received as per the provisions of the Companies Act, 2013

Note 2. Transaction by way of operation of law as Nectar Lifesciences USA LLC, a wholly owned subsidiary is dissolved.

Note 3. Unsecured Interest free loan received as an obligation from the promoter as per the One time restructuring with Banks in FY 2021-22, already approved by the Board of Directors. There is no resource has been transferred or proposed to be transferred from the Company.

Note 4. Opening and closing balance of Investment in subsidiaries during the half year ended March 31, 2023 are not given where there was no transaction .

For **Nectar Lifesciences Limited**

Date: 26-05-2023

Place: Chandigarh

(Sushil Kapoor)

**Chief Financial Officer**